✕
Get authentic, real-time news that helps you fight COVID-19 better.
Install for doctors. It's free.
Install for doctors. It's free.
Researchers who studied the DNA of 2,700 COVID-19 patients in 208 intensive care units across Britain found that five genes involving in two molecular processes - antiviral immunity and lung inflammation were central to many severe cases.
The genes called IFNAR2, TYK2, OAS1, DPP9 and CCR2 partially explain why some people become desperately sick with COVID-19 while others are not affected, said Kenneth Baillie, an academic consultant in critical care medicine at Edinburgh University who co-led the research.
The findings should help scientists speed up the search for potential drugs for COVID-19 by conducting clinical trials of medicines that target specific antiviral and anti-inflammatory pathways.
The team also found that a boost in the activity of the INFAR2 gene could create protection against COVID-19 because it is likely to mimic the effect of treatment with interferon.
Dexamethasone and a newly developed antiviral called remdesivir are the only drugs authorised around the world to treat COVID-19 patients although remdesivir is not recommended for severe cases of the disease and has had mixed results in trials.
Source:
https://www.nature.com/articles/s41586-020-03065-y
The genes called IFNAR2, TYK2, OAS1, DPP9 and CCR2 partially explain why some people become desperately sick with COVID-19 while others are not affected, said Kenneth Baillie, an academic consultant in critical care medicine at Edinburgh University who co-led the research.
The findings should help scientists speed up the search for potential drugs for COVID-19 by conducting clinical trials of medicines that target specific antiviral and anti-inflammatory pathways.
The team also found that a boost in the activity of the INFAR2 gene could create protection against COVID-19 because it is likely to mimic the effect of treatment with interferon.
Dexamethasone and a newly developed antiviral called remdesivir are the only drugs authorised around the world to treat COVID-19 patients although remdesivir is not recommended for severe cases of the disease and has had mixed results in trials.
Source:
https://www.nature.com/articles/s41586-020-03065-y
1 / 1
Dr. T●●●●z H●●●●●●i and 2 other likes this
Like
Comment
Share
